CD274 and breast cancer: Niraparib combined with anti-PD-1/PD-L1 therapy increased the infiltration of immune cells into tumor bed and slowed the tumor growth in BRCA-proficient breast cancer, sarcoma, lung squamous cell carcinoma, and colon adenocarcinoma, as well as bladder cancer [120].